Clinical trial
MITO-6: Capecitabine in Platinum Resistant Ovarian Cancer
NCT00403429 · National Cancer Institute, Naples, Other · Completed
Key facts
| NCT number | NCT00403429 |
|---|---|
| Title | MITO-6: Capecitabine in Platinum Resistant Ovarian Cancer |
| Official title | Phase II Study With Capecitabine as Monotherapy in the Treatment of Platinum Resistant or Refractory Ovarian Cancer. |
| Lead sponsor | National Cancer Institute, Naples, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer |
| Intervention type | Drug |
| Interventions | capecitabine |
| Enrollment | 36 |
| Start date | Mar 1, 2006 |
| Primary completion | Jan 1, 2008 |
| Completion | Jul 1, 2008 |
| First posted | Nov 23, 2006 |
| Last update posted | Jan 14, 2016 |
| Countries | Italy |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: